Literature DB >> 10571121

Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production.

M Takami1, J T Woo, K Nagai.   

Abstract

Fusion and activation of osteoclasts are the final two events in osteoclastic bone resorption. To investigate the regulatory mechanism of these events, mononuclear osteoclasts (preosteoclasts, pOCs) were isolated from co-cultures of mouse osteoblastic cells and bone marrow cells. Most of the pOCs cultured without any additives died within 12 h. Survival of pOCs was supported by addition of either osteoblastic cells or macrophage-colony-stimulating factor (M-CSF). pOCs began to fuse with each other after culture for 12 h in the presence of osteoblastic cells or M-CSF. However, the properties of multinucleated osteoclast-like cells (OCLs) induced by osteoblastic cells were considerably different from those induced by M-CSF. Fusion of pOCs induced by osteoblastic cells was retarded after culture for 24 h. In contrast, M-CSF-induced fusion of pOCs continued throughout the 48-h culture period, which was not inhibited by addition of calcitonin. When pOCs together with osteoblastic cells were cultured for 48 h on dentine slices, many resorption pits were formed on the slices. Calcitonin completely inhibited the fusion and pit-forming activity of pOCs treated with osteoblastic cells. Resorption pits were hardly detected on dentine slices in pOC cultures treated with M-CSF. Osteoblastic cells prepared from osteopetrotic (op/op) mice, which cannot produce functional M-CSF, stimulated the fusion and pit-forming activity of pOCs. Recombinant RANKL (receptor activator of NF-kappaB ligand), a cytokine which is produced by osteoblastic cells and is responsible for osteoclast differentiation, induced the fusion and pit-forming activity of pOCs. These results suggested that osteoblastic cells are involved in fusion and activation of osteoclasts through a mechanism independent of M-CSF production. RANKL appears to be responsible for fusion and activation of osteoclasts induced by osteoblastic cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571121     DOI: 10.1007/s004419900092

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  8 in total

1.  Neoadjuvant denosumab for the treatment of a sacral osteoblastoma.

Authors:  Jeremy J Reynolds; Dominique A Rothenfluh; Nick Athanasou; Shaun Wilson; David C Kieser
Journal:  Eur Spine J       Date:  2018-01-22       Impact factor: 3.134

2.  R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts.

Authors:  Arei Miyamoto; Masamichi Takami; Akifumi Matsumoto; Ayako Mochizuki; Takako Yamada; Keita Tachi; Isao Shibuya; Tomoya Nakamachi; Seiji Shioda; Kazuyoshi Baba; Tomio Inoue; Yoichi Miyamoto; Mijung Yim; Ryutaro Kamijo
Journal:  Cytotechnology       Date:  2012-02-23       Impact factor: 2.058

3.  Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.

Authors:  Je-Tae Woo; Makoto Kawatani; Masanori Kato; Toshimasa Shinki; Takayuki Yonezawa; Naoki Kanoh; Hiroshi Nakagawa; Masamichi Takami; Kun Hyung Lee; Paula H Stern; Kazuo Nagai; Hiroyuki Osada
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

Review 4.  Green tea and bone metabolism.

Authors:  Chwan-Li Shen; James K Yeh; Jay J Cao; Jia-Sheng Wang
Journal:  Nutr Res       Date:  2009-07       Impact factor: 3.315

5.  Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice.

Authors:  Hyunsoo Kim; Han Kyoung Choi; Ji Hye Shin; Kyung Hee Kim; Ji Young Huh; Seung Ah Lee; Chang-Yong Ko; Han-Sung Kim; Hong-In Shin; Hwa Jeong Lee; Daewon Jeong; Nacksung Kim; Yongwon Choi; Soo Young Lee
Journal:  J Clin Invest       Date:  2009-03-02       Impact factor: 14.808

6.  Osteoclast activated FoxP3+ CD8+ T-cells suppress bone resorption in vitro.

Authors:  Zachary S Buchwald; Jennifer R Kiesel; Richard DiPaolo; Meghana S Pagadala; Rajeev Aurora
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

7.  Rac1 Inhibition Via Srgap2 Restrains Inflammatory Osteoclastogenesis and Limits the Clastokine, SLIT3.

Authors:  Bongjin Shin; Justine Kupferman; Ewoud Schmidt; Franck Polleux; Anne M Delany; Sun-Kyeong Lee
Journal:  J Bone Miner Res       Date:  2020-01-09       Impact factor: 6.741

8.  Substance P modulates bone remodeling properties of murine osteoblasts and osteoclasts.

Authors:  Tanja Niedermair; Stephan Schirner; Raphael Seebröker; Rainer H Straub; Susanne Grässel
Journal:  Sci Rep       Date:  2018-06-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.